Plain-English translation of NCT06322667 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer's Disease research guide →This is a real-world study that follows people with early Alzheimer's disease who are already being treated with lecanemab. Researchers want to understand what brain imaging changes (called amyloid-related imaging abnormalities) may happen during treatment with this medication, and how doctors decide to adjust or continue treatment when these changes appear.
Lecanemab is a newer treatment for early Alzheimer's disease, and doctors need to understand how often imaging changes occur in regular medical practice, what those changes look like, and the best ways to manage them to keep patients safe and getting the most benefit from treatment.
You likely qualify if…
You likely don't qualify if…
You will continue taking your medication as your doctor prescribes, and researchers will observe you over time (up to 156 weeks, or about 3 years). Your doctors will perform brain imaging scans at routine visits and share information about any imaging changes and how they are managing your treatment. You will not be asked to do anything extra beyond your normal medical care.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Japan
Sponsor
Eisai Co., Ltd.
Enrollment target
~5,000 participants
Started
February 2024
Primary completion
December 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Eisai Inquiry Service.
Eisai Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.